Pharma BD Deal Intelligence
BMS acquired Mirati Therapeutics for $4.8B for targeted cancer therapies.
FDA granted accelerated approval on June 21, 2024 to adagrasib (KRAZATI) plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic…
BMS completes acquisition of Mirati for up to $5.8 billion including contingent value rights, bolstering its oncology pipeline with the KRAS G12C inhibitor…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
BMS acquired Mirati Therapeutics for $4.8B for targeted cancer therapies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Mirati Therapeutics (this deal) | 2023 | $4.8B | 66 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Oncology deals